The US Food and Drug Administration has granted Orphan Drug Designation to HUTCHMED (LSE:HCM)'s sovleplenib for primary immune thrombocytopenia. The designation could bring seven years of US market exclusivity if the drug is approved for that use.
What was announced
HUTCHMED (China) Limited, which is quoted on AIM and Nasdaq under LSE:HCM and in Hong Kong under 13, announced on 29 October 2026 that the US FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia, or ITP.
Sovleplenib is a novel, selective, oral inhibitor of spleen tyrosine kinase, known as Syk, taken once daily. ITP is an autoimmune disorder that increases the risk of bleeding. According to the company, platelet destruction in ITP is mediated by Syk-dependent phagocytosis, which is why it regards Syk inhibition as a promising approach to the disease.
HUTCHMED retains all worldwide rights to sovleplenib, so no partner shares in the designation or in any future US commercial rights, according to the release.
What the designation means
The FDA grants Orphan Drug Designation to medicines intended for rare conditions that affect fewer than 200,000 people in the United States. The designation does not itself constitute approval. However, if sovleplenib is approved for the designated indication, HUTCHMED would be eligible for several benefits: seven years of US market exclusivity for that indication, tax credits for qualified clinical trials, waivers of user fees under the Prescription Drug User Fee Act and specialised regulatory guidance from the FDA during development.
The announcement did not give any timetable for a US regulatory submission, nor did it say whether a US clinical trial is planned or under way.
The disease and the market
HUTCHMED's release sets out the scale of ITP. It cites an incidence in adults of 3.3 per 100,000 people a year and a prevalence of 9.5 per 100,000. The company estimates there are about 110,000 patients in China, and about 56,000 across the United States, Germany, France, Italy, Spain, the UK and Japan. It also says up to 145,000 people have chronic ITP in the major pharmaceutical markets excluding China.
The release notes that fatigue is reported in up to 39% of adults with ITP, and that many patients develop resistance to treatment and relapse, which the company presents as evidence of unmet medical need.
Progress in China
Sovleplenib is further advanced in China than in the United States. New Drug Applications are under review by China's National Medical Products Administration for two indications: primary ITP, supported by the pivotal ESLIM-01 trial, and warm antibody autoimmune haemolytic anaemia, supported by the pivotal ESLIM-02 trial.
The announcement did not include patient numbers, response rates or other efficacy and safety results from either trial, and it gave no expected timing for decisions by the Chinese regulator. It also contained no comment from HUTCHMED's management, and no financial details on development spending for the programme.
What to watch next
The key near-term milestones are the Chinese regulatory decisions on the two sovleplenib applications, which would mark the drug's first approvals if granted. For the US, investors may watch for any disclosure of a development and regulatory pathway that would allow HUTCHMED to make use of the orphan designation, including whether the company intends to run additional trials or seek a partner for markets outside China, given that it currently holds all worldwide rights.
The company's forward-looking statements highlight risks including clinical outcomes, the need for regulatory approval and commercial acceptance. No financial guidance relating to sovleplenib was provided in the announcement. HUTCHMED's nominated adviser and joint broker is Panmure Liberum, with Cavendish and Deutsche Numis acting as joint brokers.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...